Navigation Links
Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
Date:1/13/2014

LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ --

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg.

Debiopharm is investigating the efficacy and safety of the gonadotropin releasing hormone (GnRH) agonist analog triptorelin pamoate 6-month formulation in the treatment of children suffering from central (GnRH-dependent) precocious puberty (CPP). CPP is defined by pubertal development occurring before the age of 8 years in girls and 9 years in boys, which is not secondary to exposure to sex steroids of adrenal or gonadal origin (peripheral precocious puberty). This 6-month formulation offers an excellent treatment option in a pediatric indication due to less frequent injections. No GnRH agonist 6-month formulation is currently approved for treatment of precocious puberty. The study is an international, multicenter, non-controlled phase III study on the efficacy, pharmacokinetics and safety of two consecutive intramuscular injections of the triptorelin pamoate 22.5 mg 6-month formulation over 12 months. The protocol has gone through the US Food and Drug Administration (FDA) Special Protocol Assessment procedure. The recruitment has been completed and the results are expected in Q4 2014.

"We are very happy to have completed the recruitment in this study," said Eija Lundström, Medical Director responsible for this project at Debiopharm International. "We are looking forward to the results at the end of this year as we believe that the 6-month formulation will simplify the treatment of CPP and make it more tolerable for this young population of patients."


'/>"/>

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
2. Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast
3. Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
4. Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
5. Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
6. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
7. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
8. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
9. Practice Fusion Partners with Healthagens Practice iQ to Help Physician Groups Perform as ACOs
10. Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
11. FDA Warns of Health Complications from Transvaginal Mesh Erosion, Says Life Care Solutions Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)...  Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that ... ROTH Conference on Wednesday, March 11, 2015, at 10:30 a.m. ... Carlton Laguna Niguel in Dana Point, CA. ... and Chief Executive Officer of Palatin Technologies, will provide an ... About Palatin Technologies, Inc. Palatin Technologies, Inc. ...
(Date:3/6/2015)... , March 6, 2015   Prime Therapeutics ... more than 26 million members, today released the following ... (FDA) approval of the first biosimilar to enter the ... Drug Administration (FDA) approval of Sandoz,s Zarxio® to treat ... patients, is a major milestone in our country,s journey ...
(Date:3/6/2015)... März 2015  Unfors RaySafe, Marktführer für ... dem European Congress of Radiology (ECR) in ... 1.000. Installation seines Systems zur Strahlendosimetrie RaySafe ... http://photos.prnewswire.com/prnh/20150304/179432LOGO Das RaySafe i2 ... Informationen über die Dosis der Röntgenstreustrahlung gibt, ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 3
... Presented at the 2008 AACR Annual Meeting, SOMERSET, ... today announced that Dr. Intae Lee with the University ... a,promising radiation sensitizer for lung cancer treatment. Dr. Lee ... a poster at the 2008 American,Association of Cancer Research ...
... April 14, at 8:30 a.m. E.T. at ... http://www.isispharm.com , ... ) announced additional results from its,ongoing Phase 2 open-label extension (OLE) ... exposed to,mipomersen for as long as 16 months, the safety profile ...
Cached Medicine Technology:Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 2Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6
(Date:3/6/2015)... (PRWEB) March 06, 2015 Saving Moses, ... around the world is traveling to Angola, Africa March ... of their malnutrition program. , This will be the ... in Angola, demonstrating their commitment to the region’s population ... The team will engage with the mothers and babies ...
(Date:3/6/2015)... 2015 Ticket Down is a reputable source ... at the Moda Center. After being away from the ... showing no signs of letting up on his “Garth Brooks ... his wife, Trisha Yearwood, to venues around the United States. ... critically acclaimed tour to the Moda Center in Portland, OR. ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 ... known as the pharmacokinetics of a drug refers to ... pharmaceutical compound inside an organism. When toxicity studies are ... or ADMET or ADME/Tox. Increasing focus on lowering costs ... of ADME-toxicology testing worldwide. The traditional drug development model ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues ... organization has hired two new Scientific Program Officers, Amanda ... report to Grace Pavlath, Ph.D, who joined MDA late ... Director, and together will lead MDA as it accelerates ... for various types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... “On Tap” takes the audience on a journey ... the silver screen and to modern day rhythm tap. ... their famous eye-high kicks! Producers, directors and choreographers Mary Six ... dancing in this robust show, showcasing one of the only ... , “On Tap” is proud to host guest stars ...
Breaking Medicine News(10 mins):Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
... NASHVILLE, Tenn., Nov. 10 Healthcare Realty,Trust Incorporated (NYSE: ... quarter,ended September 30, 2008. Funds from operations ("FFO") per ... same period in 2007. FFO,per diluted common share totaled ... with the prior year,s $1.13. FFO would have been ...
... patients or women who want to delay childbirth , , ... the ability to freeze and transplant ovaries, a development ... therapy. , "We can transplant ovaries without any loss ... normally whether it,s fresh or frozen," said co-researcher Dr. ...
... Omega Protein Corporation,(NYSE: OME ), the nation,s ... products, today reported net income of $3.1 million (17,cents ... to net income of,$7.2 million (42 cents a share) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20030516/OMEGALOGO ), Revenues for the third ...
... Inc. ( www.infotrieve.com ), the global leader in business service solutions ... Content SCM software solution at the biopharma company UCB, headquartered in ... ... EON) November 10, 2008 -- Content SCM is Infotrieve,s revolutionary ...
... Thermage, Inc.,(Nasdaq: THRM ), a leader in ... results for the third quarter ended,September 30, 2008. Reliant ... quarter., Thermage revenue for the third quarter of ... million for the third quarter of 2007. Domestic,revenue decreased ...
... LAKE FOREST, Ill., Nov. 10 Hospira, Inc.,(NYSE: ... medication delivery,company, announced today that Ken Meyers has ... Development. In this,capacity, he will lead the global ... high-performance culture and organizational excellence.,Meyers succeeds Henry Weishaar, ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Results 2Health News:Healthcare Realty Trust Announces Third Quarter Results 3Health News:Healthcare Realty Trust Announces Third Quarter Results 4Health News:Healthcare Realty Trust Announces Third Quarter Results 5Health News:Healthcare Realty Trust Announces Third Quarter Results 6Health News:Healthcare Realty Trust Announces Third Quarter Results 7Health News:Healthcare Realty Trust Announces Third Quarter Results 8Health News:Healthcare Realty Trust Announces Third Quarter Results 9Health News:Freezing Ovaries Preserves Fertility, Scientists Report 2Health News:Freezing Ovaries Preserves Fertility, Scientists Report 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 2Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 4Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 5Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 2Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 2Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 4Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 5Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 6Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 7Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 8Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 9Health News:Hospira Names Ken Meyers to Lead Human Resources 2
20 GA TITANIUM RETINAL FORCEPS...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Permits rotation of the globe during examination. Overall length,123mm....
Medicine Products: